Pfizer, BioNTech said that laboratory tests showed that the ...

Pfizer, BioNTech said that laboratory tests showed that the third dose of the COVID-19 vaccine can neutralize the Omicron variant. The neutralizing effect of receiving two doses of the vaccine is significantly poor, and the two doses can still prevent serious diseases. A vaccine against the Omicron variant will continue to be developed and is expected to be launched before March next year, in case it is needed to adapt.
Pfizer and BioNTech stock prices rose sharply before the market.
$BioNTech(BNTX.US)$
$Pfizer(PFE.US)$